4598 Delta-Fly Pharma, Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4598

TSE Growth

Delta-Fly Pharma, Inc.

660

JPY

-17

(-2.51%)

Dec 23, 3:30 pm JST

4.21

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

655

Dec 23, 5:41 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	300	-852	-859	-862	-187.3	0	May 14, 2021	J-GAAP
Mar, 2022	300	-961	-964	-967	-178.6	0	May 13, 2022	J-GAAP
Mar, 2023	0	-1,315	-1,325	-1,328	-234.5	0	May 15, 2023	J-GAAP
Mar, 2024	0	-1,403	-1,426	-1,429	-198.8	0	May 15, 2024	J-GAAP
Mar, 2025 Guidance	ー	-1,817	-1,827	-1,829	-198.1	0	May 15, 2024	J-GAAP
YoY	－	-29.5%	-28.1%	-28.0%	+0.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 15, 2019	ー	-1,066	-1,066	-1,069	0	J-GAAP
-	Mar 24, 2020	100	-1,520	-1,527	-1,531	0	J-GAAP
Results	May 14, 2020	100	-1,545	-1,552	-1,555	0	J-GAAP
Mar, 2021	May 14, 2020	Available in future release
Results	May 14, 2021
Mar, 2022	May 14, 2021
	Mar 8, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Apr 21, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
Results	May 15, 2024
Mar, 2025	May 15, 2024	ー	-1,817	-1,827	-1,829	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2014	211	－	Available in future release
Mar, 2015	408	+93.4
Mar, 2016	145	-64.5
Mar, 2017	902	+522.1
Mar, 2018	150	-83.4
Mar, 2019	0	-100.0
Mar, 2020	100	－
Mar, 2021	300	+200.0
Mar, 2022	300	0.0
Mar, 2023	0	-100.0
Mar, 2024	0	－
Mar, 2025 Guidance	ー	－	-1,817	-29.5	-1,827	-28.1	-198.1	+0.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	0	-1,315	ー	-131.42	-119.10	ー	-234.5
Mar, 2024	0	-1,403	ー	-141.49	-120.08	ー	-198.8
Mar, 2025 Guidance	ー	-1,817	ー	-582.48	-430.35	ー	-198.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	902	-243	323	305	57,189
Fiscal Year	Mar, 2017	Mar, 2018	Mar, 2017	Mar, 2017	Mar, 2017

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	200	-407	-409	-410	-75.7	0	May 13, 2022	J-GAAP
Oct - Mar, 2022	0	-704	-705	-706	-124.7	0	May 15, 2023	J-GAAP
Oct - Mar, 2023	0	-810	-827	-829	-115.3	0	May 15, 2024	J-GAAP
Oct - Mar, 2024 Guidance	ー	-901	-912	-912	-98.8	0	Nov 14, 2024	J-GAAP
YoY	－	-11.2%	-10.3%	-10.0%	+14.4%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-961	-940	-940	119	1,268	95.77	J-GAAP
Mar, 2023	-1,315	-1,303	-1,303	882	844	93.16	J-GAAP
Mar, 2024	-1,403	-1,279	-1,279	1,853	1,417	96.13	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	0	-611	-620	-622	-114.9	ー	Nov 14, 2022	J-GAAP
Apr - Sep, 2023	0	-593	-599	-600	-91.9	ー	Nov 13, 2023	J-GAAP
Apr - Sep, 2024	0	-916	-915	-917	-111.4	ー	Nov 14, 2024	J-GAAP
YoY	－	-54.5%	-52.8%	-52.8%	-21.2%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	0	-415	-415	-416	-76.2	-Inf	Feb 14, 2023	J-GAAP
Jan - Mar, 2023	0	-289	-290	-290	-51.2	-Inf	May 15, 2023	J-GAAP
Apr - Jun, 2023	0	-275	-280	-280	-43.1	-Inf	Aug 14, 2023	J-GAAP
Jul - Sep, 2023	0	-318	-319	-320	-49.0	-Inf	Nov 13, 2023	J-GAAP
Oct - Dec, 2023	0	-356	-372	-372	-54.4	-Inf	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	0	-454	-455	-457	-63.6	-Inf	May 15, 2024	J-GAAP
Apr - Jun, 2024	0	-497	-499	-500	-60.8	-Inf	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	0	-419	-416	-417	-50.7	-Inf	Nov 14, 2024	J-GAAP
YoY	－	-31.8%	-30.4%	-30.3%	-3.4%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	0	－	Available in future release
Jan - Mar, 2020	100	－
Apr - Jun, 2020	0	－
Jul - Sep, 2020	100	－
Oct - Dec, 2020	0	－
Jan - Mar, 2021	200	+100.0
Apr - Jun, 2021	100	－
Jul - Sep, 2021	0	-100.0
Oct - Dec, 2021	0	－
Jan - Mar, 2022	200	0.0
Apr - Jun, 2022	0	-100.0
Jul - Sep, 2022	0	－
Oct - Dec, 2022	0	－
Jan - Mar, 2023	0	-100.0
Apr - Jun, 2023	0	－
Jul - Sep, 2023	0	－
Oct - Dec, 2023	0	－
Jan - Mar, 2024	0	－
Apr - Jun, 2024	0	－
Jul - Sep, 2024	0	－	-419	-31.8	-416	-30.4	-50.7	-3.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	200	-82	-89	-89	-19.3
Fiscal Year	Mar, 2021	Mar, 2021	Mar, 2021	Mar, 2021	Mar, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	227.41	93.1	1,324	1,232	-5,451	ー	May 13, 2022	J-GAAP
Mar, 2023	123.91	87.1	906	789	-6,780	ー	May 15, 2023	J-GAAP
Mar, 2024	149.69	83.5	1,474	1,231	-8,210	ー	May 15, 2024	J-GAAP
Apr - Sep, 2024	ー	73.9	425	314	-9,127	ー	Nov 14, 2024	J-GAAP

Delta-Fly Pharma, Inc.(4598) Financial Results